New trial suggests that doctor’s shouldn’t wait to add targeted therapy drugs to standard breast cancer treatment.More

In the face of a possible recession, stable demand for services and technologies acts as a protective barrier for healthcare…More

A 10% budget cut in R&D across the board for the biopharmaceutical industry would be felt not just in the…More

What the Maine and Maryland laws share in common, along with other state proposals, is that they call for “cost…More

Rite Aid’s relationships with health insurance plans are a priority to turning around the drugstore chain rather than another attempt…More

Deep Medicine not only provides a helicopter view of AI for drug discovery and development but goes further into the…More

The flurry of announcements and actions regarding Zantac raises more questions than it answers. What is known about the relative…More